Sjogren’s Syndrome Market - Industry Growth & Trend Analysis (2024-2032)

Sjogren’s Syndrome Market Synopsis:

Sjogren’s Syndrome Market Size Was Valued at USD 235.6 Million in 2023, and is Projected to Reach USD 318.3 Million by 2032, Growing at a CAGR of 3.4% From 2024-2032.

The Sjogren’s Syndrome is a rheumatic disease in which the particular target is the moisture producing glands of the body, those which affects most are the salivary and lacrimal glands. This condition stimulates symptoms like; dry mouth, dry eyes, fatigue and pain in the joints. It can be present alongside other autoimmune conditions, these include arthritis rheumatoid or lupus. The syndrome is classified into two types: atomic Sjogren’s syndrome that exists alone and systemic Sjogren’s syndrome that goes hand in hand with other autoimmune disorders. The global Sjogren’s Syndrome market is defined by diagnostic tools, treatment drugs, as well as the supportive products and services that enhance patient’s quality of life. The market for autoimmune diseases is expanding due to the rising incidence of Sjogren’s Syndrome, the development of new biologics medications and improved knowledge about such diseases.

The market of Sjogren’s Syndrome has been gradually growing over the past few years because of the growing number of such diseases across the world. Working on the investigated topic, many researchers found that Sjogren’s Syndrome is more characteristic of middle-aged women, which once again proves the need for gender-targeted research and medical programs. Diagnostic services in this market comprise blood analysis, imaging techniques, and biopsy, with therapeutic services comprised of immunosuppressive medication, corticosteroids, and biological agents. New growing trends in research are expected to significantly contribute to the growth of the sector by offering new end markets for products such as biologics and targeted therapies.

The market is also touching its peak because of the increasing trend of health care expenditure and the increasing support towards the disease and disorder through government and non-government sectors. Also, leading drug manufacturers are also expending efforts in clinical trials of novel immune-targeted drugs with diverse pathways which should extend the therapeutic opportunities. However, the following challenges prevail; late diagnosis, no definitive biomarkers and high cost attached to novel therapeutic options.

Sjogren’s Syndrome Market Trend Analysis:

Increasing Focus on Biologics

• Another of the shifts happening within the context of the Sjogren’s Syndrome market is the noticeable shift towards biologics and targeted therapies. Antibodies and recombinant proteins, including B-cell inhibitors and TNF-alpha inhibitors, are gradually receiving more attention due to the fact that they may offer a more selective means of regulating immune changes than standard immunosuppressives. For example, the rituximab, belimumab treatment has been effective in clinical studies for the severe forms of Sjogren’s Syndrome. This shift towards biologics is the general global trend in managing autoimmune diseases and applies precision medicine as the foundation.

Rising Awareness and Diagnosis Rates

• The increasing level of knowledge of autoimmune diseases is one of the main opportunities for the Sjogren’s Syndrome market. Educations from the Sjögren’s Foundation and collaborations between Pharma and healthcare organizations are allowing higher rates of early diagnosis. In addition, research on identifying more specific biomarkers unique to Sjogren’s Syndrome may have a great impact on diagnostics in the future, as it will increase the protection of research subjects and will help identify more individuals with the disease and begin treating them earlier. Target markets, especially in Asia-Pacific and Latin America, remain underpenetrated, yet rising healthcare investment and increasing disposable income should pave the way for further diagnostics and treatment consumption.

Sjogren’s Syndrome Market Segment Analysis:

Sjogren’s Syndrome Market is Segmented on the basis of type, Drug and Distribution Channel.

By Type, Primary segment is expected to dominate the market during the forecast period

• The first segment of the market is expected to hold the largest share of the Sjogren’s Syndrome market through the forecast year. Primary Sjogren’s Syndrome is diagnosed without association to other autoimmune diseases; its diagnosis involves a clinical evaluation of the patient to identify their symptoms, an assessment of salivary gland function as well as immunologic tests. The primary cause for this segment’s high importance is that primary Sjögren’s Syndrome is more common than secondary ones. In addition, higher, proactive campaigns for the early signs of the disease are driving the growth of this segment.
• Diagnostic capabilities are also a crucial factor in diagnosing primary Sjogren’s Syndrome because recent developments such as salivary gland imaging and genetic tests have increased the diagnoses to a large extent. Also, discovery and development activities related to the etiology of primary Sjogren’s Syndrome work on target promising therapies, and hence are beneficial to this segment of the market.

By Drug, Antimalarial Quinolines segment expected to held the largest share

• The Sjogren’s Syndrome market by drug type is expected to be led by antimalarial quinolines like hydroxychloroquine. They are used in treatment of joint pain, fatigue and skin lesions that are characteristic of the syndrome due to immunomodulating effect. Because of the strong evidence of safety and efficacy, favourable price-performance ratio and wide acceptance by prescribing decision-makers, antimalarials quinolines are likely to remain dominant.
• Thus, besides the therapeutic uses the antimalarial quinolines are also used in combination with other immunosuppressants in a severe, enlarging the spectrum. Further research and development in an attempt to enhance the potency of these drugs, and at the same time to remove, reduce or control their negative effects to an acceptable level, should also help to cement their hold in the market.

Sjogren’s Syndrome Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• In 2023, North America led the Sjogren’s Syndrome market owning about 35-40% of the global market. The dominance is due to the fact it has established healthcare facilities, a higher level of health and research awareness and more focus on development and research of autoimmune disorders. Among the region, the United States is more prominent because of the market stakeholders, a strong clinical trial environment, and acceptable reimbursement policies. Further, the North American high-biologic-reimbursement market is supplemented by the increasing utilization of sophisticated diagnostic technologies.

Active Key Players in the Sjogren’s Syndrome Market:

• AbbVie Inc. (USA)
• AstraZeneca (UK)
• Bristol-Myers Squibb (USA)
• Daiichi Sankyo Company (Japan)
• Eisai Co., Ltd. (Japan)
• Eli Lilly and Company (USA)
• F. Hoffmann-La Roche AG (Switzerland)
• GlaxoSmithKline plc (UK)
• Johnson & Johnson (USA)
• Novartis AG (Switzerland)
• Pfizer Inc. (USA)
• Sanofi (France)
• Teva Pharmaceutical Industries Ltd. (Israel)
• UCB S.A. (Belgium)
• Zydus Lifesciences (India)
• Other Active Players